Targeted Therapy of Acute Myeloid Leukemia (eBook)

1. Introduction/Perspective  Michael Andreeff 2. Genetics and Classification of Acute Myeloid LeukemiaAlison R. Walker and Guido Marcucci: 3. Proteomics of AML to guide Selection of TherapySteven M. KornblauPart I: Apoptosis 4. Roles of Apoptosis Regulating Bcl-2-Family Genes in AMLJohn C. Reed5. Bcl-2 family: Translational aspectsPrithviraj  Bose and Steven Grant  6. IAP Family and Proteins as Therapeutic Targets for Acute Myeloid LeukemiaBing  Carter and Michael Andreeff7. TP53 Mutations in Acute Myeloid LeukemiaClaudia  Haferlach and Torsten Haferlach8. Targeting p53 Tumor Suppressor for AML TherapyKensuke Kojima and Lyubumir T. Vassilev9. AML-Selective Apoptosis Induction by rationally designed Death Ligand Fusion ProteinEdwin Brenner and Wijnand HelfrichPart II: Signaling 10. PIM Kinases in AMLVarsha. Gandhi and L. Chen11. Development of Midostaurin as a Tyrosine Kinase InhabitorRichard M. Stone and Gabi Motyckova12. FLT3 in AMLNaval Daver Farhad Ravandi13. FLT3-ITD. Clinical (Sorafenib/AC220)Naveen Pemmeraju and Jorge E. Cortes14. Nucleophosmin (NPM1) Kapil N. Bhalla and Ramesh Balusu15. Raf/MEK PathwayJames A. McCubrey, Linda.S. Steelman, Joerg Baesecke, and AlbertoM. Martelli16. The Role of Translational Medicine in Optimization of Therapies targeting the RAS-MAP Kinase PathwayJudith S. Sebolt-Leopold 17. Clinical Use of Farnesyltransferase InhititorsChezi Ganzel and Jacob M. Rowe18. The P13K-AKT-mTOR signaling Network in AMLBrandon Beagle and David A. Fruman19. Targeting the P13 Kinase-mTOR Signaling Pathway in AMLMartin Carroll20. Aurora kinasesSubrata Sen, Hiroshi Katayama21. The Clinical Development of Aurora Kinase Inhibitors in Acute Myeloid LeukemiaKevin R. Kelly, Ciara L. Freeman, and Francis J. GilesPart III: Epigenetics22. AML-DeacetylasesMargherita Ghisi and Ricky W. Johnstone23. Methylation in AML-Clinical Applications Naveen Pemmaraju, Guillermo Garcia-Manero, Farhad Ravandi Part IV: Nuclear Receptors24. Topic: RARa/RXR  Part: BasicHugues de The25. Arsenic Trioxide in Untreated APLElihu H. Estey 26. Targeting PML-RARα with RetinoidsEytan M. Stein  and Martin S. Tallman27. NR4A Orphan Receptors as Drug TargetsSteven H. Safe, Syng-Ook Lee, Cong Meng, and Beiyan ZhouPart V: Cell Surface Receptors 28. Antibody-based Therapeutics Targeting CD33, CD45, and CD66Roland B. Walter, Oliver W. Press, and Irwin D. BernsteinPart VI: Stem Cells 29. New Heterogeneity of the Leukemic Stem CellsDominique Bonnet30. Targeting Leukemia Stem CellsDuane C. Hassane, Monica L. GuzmanPart VII: Microenvironment 31. Regulation of Hematopoiesis by CXCL12/CXCR4 SignalingDaniel C. Link32. CXC4/CXCL12 as a Therapeutic TargetGeoffrey L. Uy, John F. DiPersio33. VLA-4: A Cell’s Consequential EncounterThalia Papayannopoulou34. VLA-4 Function and Prognosis in Acute Myeloid LeukemiaPamela S. Becker, Frederick R. Appelbaum35. VLA4 in Acute Lymphoblastic LeukemiaHalvard Boenig, Yong-Mi KimPart VIII: Hypoxia 36. The Leukemic Bone Marrow Microenvironment: Targeting Hypoxia with Hypoxia Activated Pro-DrugsJuliana Benito, Marina Konopleva, William R. WilsonPart IX: Micro-RNAs 37. Topic: miRs as Therapeutic TargetsMaitri Shah, George Calin38. Clinical Implications of MicroRNAs in AMLParvathi Ranganathan, Ramiro GarzonPart X: Metabolism 39. Inhibition of Glycolysis as a Therapeutic Strategy in Acute Myeloid LeukemiasR. Laister, Tak W. Mak, Mark Minden40. Molecular and Biochemical Basis for the Reprogramming of Intermediary Metabolism in Leukemia CellsIsmael Samudio, Juliana VelezPart XI: Cell Therapy 41. NK Cell Immunotherapy for AMLLaurence James N. Cooper, Dean Anthony Lee, Elizabeth Shpall42. Allogeneic and Autologous T cell Strategies to Enhance Targeting of Acute Myeloid LeukemiaGerrit Weber, Catherine M. Bollard, John Barrett43. Indications for Hematopoietic Transplantation for AMLSairah Ahmed, Richard Champlin44. Mesenchymal Stem/Stromal Cell Targeted Therapies for Solid Tumors and Hematological MalignanciesChristopher H Booth, Lysette Mutkus, Karen Bussard, Erika Spaeth, Michael Andreeff, Frank C Marini